AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04194983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oils and plant fat
Description: 12-weeks, 3x per day
Study NCT03703752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-detector CT scan
Description: This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
Study NCT00594880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha 2a, 90 mcg/week sc
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Study NCT02217215 — intervention group
Intervention type: DEVICE
Intervention: CNDS Advanced Cervical Scan
Description: Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated.
Study NCT03557671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rice formula
Description: new rice based thickened formula
Study NCT03557671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice formula
Description: new rice based thickened formula
Study NCT03557671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: formula previously tolerated by the subject - only for the 1st part of the study
Study NCT03557671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: formula previously tolerated by the subject - only for the 1st part of the study
Study NCT02936882 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preoperative gastric ultrasonography
Description: Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
Study NCT01344551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Drink
Description: High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
Study NCT01344551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Drink
Description: High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
Study NCT01254747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
Study NCT01254747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)
Description: Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
Study NCT01254747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens (DAILIES AquaComfort Plus)
Description: Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
Study NCT01254747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)
Description: Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
Study NCT02406677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study voucher card
Description: Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
Study NCT01114880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
Study NCT01114880 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Description: Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
Study NCT01114880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Prefilled syringe, matching placebo administered subcutaneously every other week
Study NCT02817906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Study NCT02817906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01173432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
Study NCT01708343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIMMST
Study NCT01708343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIMMST
Study NCT01708343 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: DIMMST
Study NCT02273258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02273258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02625064 — intervention group
Intervention type: OTHER
Intervention: Blood samples collection before treatment
Study NCT02625064 — intervention group
Intervention type: OTHER
Intervention: Blood samples collection after treatment
Study NCT02625064 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker proteomic analysis
Study NCT01690377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDC or myDC
Description: PDC or myDC; first patient 0.3 \* 10E6 PDC; second and third 1 \* 10E6 PDC; fourth and fifth 3 \* 10E6 PDC.
Study NCT04033302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7-specific CAR gene-engineered T cells
Description: Infusion of CD7-specific CAR-T cells
Study NCT02145468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg twice daily
Description: Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
Study NCT02145468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo twice daily
Description: Subjects will receive placebo as film-coated, round, plain faced tablets.
Study NCT02145468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
Study NCT02145468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
Study NCT03023553 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection
Study NCT03023553 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: Influenza Virus Vaccine Live, Intranasal Spray
Study NCT02408991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: Neupogen is given as an injection in your skin every three days for a total of 5 doses.
Study NCT02408991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Art-Assist Device
Description: The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
Study NCT02372344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585
Description: Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
Study NCT03988140 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dental Implant Placement and subsequent prosthetic reabilithation
Description: Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
Study NCT03988140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement and subsequent prosthetic reabilithation
Description: Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
Study NCT03666416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training
Description: Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
Study NCT04279080 — intervention group
Intervention type: OTHER
Intervention: low anterior resection syndrome evaluation
Description: evaluation of postoperative functional bowel outcome
Study NCT05897866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management
Description: Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
Study NCT04354415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel or trigger finger release
Description: Carpal tunnel or trigger finger release with and without the use of tourniquet
Study NCT04354415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel or trigger finger release
Description: Carpal tunnel or trigger finger release with and without the use of tourniquet
Study NCT04530669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Tone Power Therapy
Description: High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort.
Study NCT04530669 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercise program
Description: physical therapy conventional selected exercise program inform of functional activities of daily living
Study NCT04530669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: physical therapy conventional selected exercise program inform of functional activities of daily living
Study NCT01299883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated vs Non-integrated Risk Education
Description: Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
Study NCT03452462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing
Description: Programming of either Direct His Bundle pacing or biventricular pacing
Study NCT03452462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing
Description: Programming of either Direct His Bundle pacing or biventricular pacing
Study NCT03297229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Description: Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
Study NCT01609062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
Study NCT01609062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
Study NCT01436253 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle Changes
Description: Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
Study NCT01436253 — intervention group
Intervention type: DRUG
Intervention: Hypolipemics
Description: Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
Study NCT03408977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probe meal
Description: The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
Study NCT00081822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clofarabine
Description: Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
Study NCT00081822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 \& 3.
Study NCT03399851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amplatzer Amulet for left atrial appendage closure
Description: The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
Study NCT03399851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Watchman/FLX for left atrial appendage closure
Description: The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
Study NCT04152057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate Tablets
Description: 400mg/d,po qd,q3w, 4 cycles
Study NCT04152057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: 125mg/m2,ivggt,d1,q3w,4 cycles.
Study NCT04152057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
Study NCT00623805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a solution in single-use vials.
Study NCT00623805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a solution in single-use vials.
Study NCT00623805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was supplied as film-coated tablets.
Study NCT00623805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine was supplied as film-coated tablets.
Study NCT00623805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was supplied as a lyophilized powder in vials.
Study NCT00623805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin was supplied as a lyophilized powder in vials.
Study NCT05039294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Physical Activity Educational Program
Description: The structure of the educational sessions includes physical education lectures, group discussions, videos, training sessions, physical activities diaries, short quizzes, and feedback after each session. The educational programs were conducted among students with intervention groups at two-level individually and in school. The individual-level includes classroom lectures that mainly emphasized the health benefits of physical activity and provided necessary information about physical activity fitness for 60 minutes and were given weekly for four weeks. In coordination with the school sports teacher, training sessions included moderate to vigorous physical activities for 45 minutes twice weekly for four weeks
Study NCT04190836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Managed Exercise Strategy
Description: The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days.
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
Study NCT03297229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values.
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.